Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of invasive adenocarcinoma by core needle biopsy~  * Fine needle aspiration allowed provided primary tumor size \< 2 cm and lymph node metastases are present~ * Excisional biopsy of the primary tumor allowed provided biopsy-positive lymph nodes are present~* Primary tumor ≥ 2 cm and/or ≥ 1 biopsy-positive lymph node~* HER2-positive disease~  * Confirmation by fluorescent in situ hybridization (FISH) requires gene amplification~ * Confirmation by immunohistochemistry (IHC) requires a strongly positive (3+) staining intensity score~* Ductal carcinoma in situ (DCIS) or synchronous DCIS of the contralateral breast regardless of prior therapy allowed~  * Synchronous invasive breast cancer not allowed~* Ipsilateral DCIS treated by local excision with or without hormonal therapy allowed~  * Those treated with radiation therapy are not allowed~* No definitive clinical or radiologic evidence of metastatic disease~* No history of invasive breast cancer~* Hormone receptor status known~* Menopausal status not specified~* ECOG performance status of 0 -1~* Absolute neutrophil count ≥ 1,200/mm³~* Platelet count ≥ 100,000/mm³~* Total bilirubin normal unless the patient has a grade 1 bilirubin elevation (normal to 1.5 times upper limit of normal \[ULN\]) resulting from Gilbert disease or similar syndrome due to slow conjugation of bilirubin~* Alkaline phosphatase ≤ 2.5 times ULN~* AST ≤ 1.5 times ULN~* Creatinine normal~* Left ventricular ejection fraction (LVEF) ≥ 55 by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within the past 3 months~* Patients with either skeletal pain or alkaline phosphatase that is \> ULN but ≤ 2.5 times ULN allowed if bone scans fail to demonstrate metastatic disease~  * Suspicious findings on bone scan must be confirmed as benign by x-ray, MRI, or biopsy~* Prior non-breast malignancies allowed if disease-free for 5 years since completion of initial treatment regimen and deemed by their physician to be at low risk for recurrence~  * Patients who had the following cancers are eligible if diagnosed and treated within the past 5 years:~    * Carcinoma in situ of the cervix~   * Colon carcinoma in situ~   * Melanoma in situ~   * Basal cell and squamous cell carcinoma of the skin~* No cardiac disease that would preclude the use of epirubicin hydrochloride or trastuzumab (Herceptin®) including any of the following:~  * Active cardiac disease~ * Angina pectoris that requires the use of antianginal medication~ * Cardiac arrhythmia requiring medication~ * Severe conduction abnormality~ * Clinically significant valvular disease~ * Cardiomegaly on chest x-ray~ * Ventricular hypertrophy on EKG~ * Patient's with poorly controlled hypertension ( i.e., diastolic greater than 100 mm/Hg)~    * Patients with hypertension that is well controlled on medication are eligible~ * History of cardiac disease~ * Myocardial infarction documented as a clinical diagnosis or by EKG or any other tests~ * Documented congestive heart failure~ * Documented cardiomyopathy~* No sensory or motor neuropathy ≥ grade 2, as defined by the NCI's CTCAE v3.0~* Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy~* Women of child bearing potential must have a negative urine or serum pregnancy test within 2 weeks of registration~* Not pregnant or nursing~* No psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements~* No non-malignant systemic disease (e.g., cardiovascular, renal, hepatic) that would preclude treatment with either of the treatment regimens~* No prior surgical axillary staging procedure~  * Prior non-excisional biopsy of an axillary node allowed~* No prior treatment for this breast cancer~  * Hormonal therapy allowed if had been given for up to a total of 28 days anytime after diagnosis and before study entry~ * Hormonal therapy must stop at or before study entry and be re-started, if indicated, following surgery~* No prior therapy with anthracyclines or taxanes for any malignancy~* No other investigational agents within the past 30 days~* No concurrent sex hormonal therapy (e.g., birth control pills, ovarian hormonal replacement therapy)~* No concurrent therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FEC-75 then Paclitaxel/trastuzumab (Type: ACTIVE_COMPARATOR): Patients receive FEC comprising fluoroucacil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.
- Paclitaxel/trastuzumab then trastuzumab/FEC-75 (Type: EXPERIMENTAL): Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.

Based on this trial design, predict the completion outcome and termination type (if applicable).